The role of minimal access surgery (MAS) in total mesorectal excision (TME) is hotly contested. Oncological outcomes are closely linked to the technical performance of surgery, specifically through the quality of the TME specimen \[[@CR1]--[@CR5]\]. Medium-term follow-up of multicentre randomised controlled trials (RCTs) suggest that laparoscopic rectal surgery can be performed without oncological compromise \[[@CR6]--[@CR8]\]; however, two recent large RCTs showed that although the majority of laparoscopic cases had acceptable specimens, laparoscopic non-inferiority could not be shown \[[@CR9], [@CR10]\]. This topic is highly pertinent as because of perceived short-term patient benefits 68% of UK rectal cancer patients presently receive a laparoscopic operation \[[@CR7], [@CR11], [@CR12]\].

The MAS revolution is facilitated by continuous technological development. Advances in laparoscopic platforms include commercially available three-dimensional (3D) HD systems. Initial adoption was hampered by poor image resolution and bulky headgear associated with unacceptable user side effects \[[@CR13]\]. Modern refinement of 3D technology has revived surgical interest as contemporary systems have overcome these issues without increasing cognitive load \[[@CR14]--[@CR16]\].

The potential advantages of 3D imaging systems on the performance or outcomes following advanced laparoscopic procedures have not been proved as the available literature predominantly focusses on trainee performance of ex-vivo box trainer tasks with significant methodological concerns raised \[[@CR14], [@CR16], [@CR17]\]. Therefore, we designed a development trial with the dual aims of comparing specialist surgical performance of laparoscopic TME surgery using 2D and 3D imaging and to generate evidence to identify and power the appropriate primary endpoint for use in a future definitive TME study.

Methods {#Sec2}
=======

A four-centre, parallel arm (1:1), stage 2b exploration study developmental randomised controlled trial was designed in keeping with the IDEAL recommendations as well as quality assurance in multicentre laparoscopic colorectal trials, 3D laparoscopic studies and CONSORT principles \[[@CR14], [@CR17]--[@CR19]\]. Ethical approval was granted by the UK National Health Service South Central - Berkshire B research ethics committee (16/SC/0118). This trial is registered (ISRCTN59485808).

Patient eligibility criteria {#Sec3}
----------------------------

Study inclusion criteria were biopsy-proven adenocarcinoma of the rectum, ≤ 15 cm from the anal verge, age 18 ≤, provision of written informed consent and the responsible colorectal multi-disciplinary team advised elective laparoscopic TME undertaken with curative intent. Neoadjuvant chemoradiotherapy use remained at the discretion of the responsible clinicians. All patients were required to undergo minimum staging of pelvic MRI, CT chest, abdomen and pelvis, tumour biopsy and full colonic assessment with either optical colonoscopy or CT colonography. Exclusion criteria were known or suspected inflammatory bowel disease, emergency, unplanned or palliative surgery, locally advanced cancers (T4a---TNM 5th edition), refusal or inability to provide informed consent and concurrent or past abdominal or pelvic malignancy. Abdominal-perineal excisions, trans-anal TME and procedures where no anastomosis was planned were also excluded.

Surgeon eligibility criteria and stereopsis testing {#Sec4}
---------------------------------------------------

Established experienced minimally invasive rectal cancer centres were approached to participate. All trial surgeons were required to have exceeded previously defined proficiency curve estimates and/or completed the UK LapCo consultant training programme as participant or tutor \[[@CR20]\]. Surgeons took the Netherlands organisation for applied scientific research (TNO) stereoscopic visual test (19th edition, Laméris Ootech BV, Utrecht, The Netherlands). Participant stereo acuity was defined as the last correctly reported image with ≤ 120 s of arc considered normal.

Developmental endpoints and sample size {#Sec5}
---------------------------------------

There was no prior 3D TME research to guide sample size calculations. To assess the impact of stereoscopic imaging on TME performance, the primary endpoint of this study was the total number of enacted intraoperative adverse events per case identified using the observational clinical human reliability analysis (OCHRA) methodology. In previous work, using a combination of open and 2D laparoscopic TME cases, we observed an average of 17 errors (± 7.02 \[[@CR21]\]) with differences in specialist performances identified \[[@CR22]\]. Using a 5% significant level, a sample size of 62 had 80% power to detect a decrease in error counts to 12. This minimally relevant 30% difference was chosen based on the difference in operative performance of laparoscopic colectomy in the UK LapCo national training programme sign off data as an estimate \[[@CR22]\]. Allowing a 15% attrition rate for conversions or loss to follow-up the recruitment target was 72.

Clinical outcomes {#Sec6}
-----------------

Pre-defined secondary endpoints were operative factors (time, blood loss, stoma creation and conversion---defined as inability to complete the dissection including the vascular ligation and/or requiring an incision larger than that needed for specimen extraction), histopathologically assessed specimen quality (plane of mesorectal excision, lymph node yield, circumferential resection margin and complete excision \[[@CR2]\]) and 30-day patient outcomes morbidity (using the Clavien--Dindo classification \[[@CR23]\], length of stay and unplanned reattendance or readmission to hospital). As 3D systems have the potential to influence surgeon cognitive load, the NASA-task load index (NASA-TLX) was completed following each case \[[@CR24]\]. This widely applied and previously validated surgeon reported system represents the most commonly used measurement method to assess cognition in the operating theatre setting \[[@CR25], [@CR26]\].

Observational clinical human reliability analysis (OCHRA) {#Sec7}
---------------------------------------------------------

To assess whether 3D imaging influenced surgical performance, assessment of the intraoperative period is required to provide detailed analysis of the intervention delivery. The OCHRA technique was adopted in keeping with previous descriptions used for the assessment of specialist performance of laparoscopic colorectal resections and the primary endpoint of a multicentre TME RCT \[[@CR21], [@CR22], [@CR27]\]. Briefly, OCHRA involves structured analysis of unedited case video to identify adverse events defined as "something that was not intended by the surgeon, nor desired by a set of rules or an external observer, or that led the task outside acceptable limits" \[[@CR28]\]. Events were further categorised by instrument used, external error mode, instrument/dissection or tissue/retraction errors (based upon the perceived principal mechanism for the event) and any resulting consequence used previously reported pre-defined coding lists (Table [2](#Tab2){ref-type="table"} and Table [4](#Tab4){ref-type="table"}). Errors occur across all task phases not just the pelvis \[[@CR21], [@CR22], [@CR27]\], therefore analysis of the entire case was performed. Operative phase of surgery was also captured using a hierarchical task analysis based upon an international consensus \[[@CR21], [@CR29]\]. Deviation from this order was not considered as an error. Video review was performed after OCHRA training including blinded analysis of 20 previously recorded 2D laparoscopic TME cases with excellent inter-rater reliability observed (Intraclass correlation co-efficient 0.916).

Equipment, setup and procedures {#Sec8}
-------------------------------

All cases were performed using Karl Storz IMAGE1 S D3-Link™ laparoscopic systems with zero or 30° 10-mm TIPCAM®1 SPIES 3D video laparoscopes. Images were displayed on 32-inch LCD HD screens (model EJ-MDA32E-K) and viewed with passive polarising glasses (Panasonic® Europe, Wiesbaden, Germany). To minimise cross-talk and facilitate optimal viewing and ergonomic positioning, precise screen location and viewing distance was at the discretion of each surgical team. All participating surgeons stated that their usual operative plan matched the previously reported international TME standardisation report \[[@CR29]\]. To maximise recruitment, generalisability of results and ethical and surgeon acceptability, no constraints on timing of surgery, operative technique, task order, instrument use or any on table decision were made. All perioperative care proceeded as per local site policies.

Data collection {#Sec9}
---------------

Video recording utilised the integrated advanced image and data acquisition system (AIDA™, Karl Storz Endoskopy GmBH, Tuttlingen, Germany). Entire cases were recorded unedited in 2D irrespective of randomisation result, deidentified and labelled with a unique study ID as sole identifier. Immediately following case completion, surgeons completed the NASA-TLX instrument and a series of 100-mm visual analogue scales capturing overall case, task and pelvic complexity. Specimen analysis was performed at each site by specialist histopathologists blinded to trial arm and in keeping with the UK Royal College of Pathologists reporting dataset including a three-point ordinal scale for plane of mesorectal dissection. Patients were prospectively followed for 30 days by dedicated research staff independent of the trial. All complications were categorised using the Clavien--Dindo classification \[[@CR30]\]. Video files were transferred to the central trial office for analysis using portable hard drives (Canvio Basics, Toshiba Europe, Weybridge, UK). Here, a second coding took place to further ensure blinded analysis.

Randomisation procedure {#Sec10}
-----------------------

To ensure allocation concealment, upon recruitment, patients were randomised centrally to the 2D or 3D arms using a pre-defined computer-generated random number list. Given the sample size, no stratification was undertaken.

Statistical analyses {#Sec11}
--------------------

The data were analysed using SPSS (v24.0; SPSS Inc, Chicago, IL, USA). All data were explored for normality with the Shapiro--Wilk test and detrended Q--Q plots and compared with parametric or non-parametric tests as appropriate. *t-*test, Mann--Whitney U and Kruskal Wallis testing were used to compare medians from normal and non-normally distributed populations. For categorical data, analysis included the use of cross tabulation, Fisher's exact test or chi-squared to test association between groups. Effect magnitude was quantified using odds ratio (OR) and 95% confidence intervals. Data are displayed as medians with interquartile ranges (IQR) unless specified. Comparative results are reported as (2D vs.3D) throughout. Analyses are reported as intention to treat except those solely based upon video analysis where the necessity for a complete case recording required a per protocol approach. Statistical significance was defined as *p* \< 0.05.

Results {#Sec12}
=======

88 patients from four sites were randomised between June 2016 and March 2018 (Fig. [1](#Fig1){ref-type="fig"}). 58% were male. Average age, body mass index and tumour height from the anal verge were 69, 28 and 8.5 cm, respectively. 23% underwent neoadjuvant chemoradiotherapy. All patient and tumour demographics were evenly distributed (Table [1](#Tab1){ref-type="table"}). Nine surgeons participated with no evidence of impaired stereo acuity (range 60--15 s of arc).

Fig. 1Trial CONSORT diagram. Three patients did not proceed to surgery. Four conversions were seen and with other exclusions 77 videos were available for OCHRA analysis

Table 1Patient demographics and tumour details2D3DMean (sd)CountColumn *N* (%)Mean (sd)CountColumn *N* (%)Age69 (11)69 (10)Gender Females2148.81635.6 Males2251.22964.4Body mass index29 (5)27 (4)Previous abdominal or pelvic surgery No2967.43373.3 Yes1432.61226.7American society of anaesthesiologists score I49.324.4 II2455.82862.2 III1125.61431.1 IV3700.0 Unknown12.312.2Neoadjuvant use None3274.43680.0 Short course radiotherapy12.300.0 Long course chemoradiotherapy1023.3920.0Tumour height (cm)8.5 (3)8.4 (3.1)Tumour height from anal verge Upper (10.1--15 cm)1023.31431.1 Mid (6.1--10 cm)2353.51840 Lower (≤ 6 cm)1023.31328.9Predominant tumour location Anterior1432.61124.4 Posterior920.9715.6 Left lateral818.6715.6 Right lateral24.7715.6 Circumferential920.91124.4 Unknown12.324.4All key patient, tumour and neoadjuvant therapy factors were equally distributed between trial arms. Tumours were predominantly mid-rectal but included equal numbers of upper and lower rectal cancers

Operative data and surgeon reported case complexity {#Sec13}
---------------------------------------------------

No differences were seen in surgeon reported overall case complexity (28 mm (IQR 18--43) vs. 31 mm (19--63), *p* = 0.399), any surgical phase or pelvic quadrants between the trial arms (Table [2](#Tab2){ref-type="table"}). No differences in surgical time (278 (95% CI 270--360) vs. 270 min (235--335), *p* = 0.34), blood loss (60 vs. 90 ml, *p* = 0.618), conversion (2 (4.9%) vs. 2 (4.8%), *p* = 0.981), defunctioning ileostomy creation (89% vs. 85%, *p* = 0.587) or anastomosis height (3 vs. 3 cm, *p* = 0.829) were seen.

Table 2Surgeon reported case difficulty2D3D*p*MedianMedianOverall case complexity28310.399Access to abdomen14130.784Splenic Flexure mobilisation21180.127IMA pedicle dissection and division22200.871Access to pelvis16180.511Identification of autonomic nerves24220.54Division of rectum19200.919Anastomosis22170.181Anterior TME Anterior TME difficulty30250.78 Oedema560.483 Fibrosis880.327 Bleeding680.4 Surgical planes14130.838Left lateral TME Left TME difficulty19220.705 Oedema790.676 Fibrosis7100.363 Bleeding9100.86 Surgical planes14160.68Right lateral TME Right TME difficulty25300.29 Oedema770.616 Fibrosis10140.316 Bleeding9120.504 Surgical planes20200.38Posterior TME Posterior TME difficulty20180.603 Oedema760.524 Fibrosis870.593 Bleeding880.941 Surgical planes16130.383100-mm visual analogue scales with 0 representing the easiest possible case were used. All figures are medians. No difference in any measure is seen between the trial arms so the Bonferroni correction was not applied. Overall the scores are relatively low for a complex procedure

Short-term patient outcomes {#Sec14}
---------------------------

A total of 110 morbidity events from 52 patients were recorded in the first 30 post-operative days (any morbidity 61.2%, median 1 per patient, IQR 0--2, range 0--5, Table [3](#Tab3){ref-type="table"}) with no difference between trial arms (59.5% vs. 62.7%, odds ratio 1.2 (95% CI 0.5--2.9), *p* = 0.834) or Clavien--Dindo classification (*p* = 0.899). Anastomotic leak rate (overall 5.9%, 4.8% vs. 7%, *p* = 0.666) and re-operation rate (7.1% vs. 4.7%, *p* = 0.666) were comparable between the arms. Non-significant differences in length of hospital stay (9 (IQR 6--18) vs. 7 (5--15) days, *p* = 0.203) and re-admissions were observed (11.9% vs. 25.6%, *p* = 0.109).

Table 330-day morbidity events with Clavien--Dindo classification \[[@CR30]\]Trial Arm\
Number of cases2D\
423D\
43Clavien--Dindo classificationIIIIIIIVIIIIIIIVIleus5453Acute kidney injury2342Urinary retention341Wound infection511Sepsis43Abdominal or pelvic collection2221High output stoma1113Urinary tract infection411Atrial fibrillation, flutter or supraventricular tachycardia311Anastomotic leak2\*\*3\*\*Anaemia2Hypertension11Nausea/vomiting11Stoma prolapse2Pneumonia11Splenic haematoma11Allergic reaction1Chest pain1Diabetic ketoacidosis1Duodenal ulcer bleed1High output drain1Hypocalcaemia1Hypotension1Ischaemic optic neuropathy1Neuropraxia1Neutropenia1Pancreatitis1Rectal bleeding1Retrograde ejaculation1Small bowel obstruction1\*Stomal bleeding1Stomatitis2Vasovagal collapse1Wound bleeding1Sum193061242172Total5654Number and nature were evenly distributed between trial arms (*p* = 0.899) with no differences seen in anastomotic leak or reo-peration rates. 40% of 2D patients and 37% of 3D patients recovered without developing any morbidity event. Asterisk denotes a re-operation took place for this indication

OCHRA analysis {#Sec15}
--------------

77 cases were analysed comprising 380 h of surgery. A total of 1377 intraoperative errors were identified (median 18 per case, IQR 14--21, range 2--49). No differences were seen between the 2D and 3D arms (18 (IQR 14--21) vs. 17 (IQR 13--22), *p* = 0.437). OCHRA categorical data are displayed in Fig. [2](#Fig2){ref-type="fig"}A--C and Table [4](#Tab4){ref-type="table"}. Apart from a reduction in overshoot errors in 3D surgery (64 vs. 48, *p* = 0.05), no differences are seen in the data. Errors took place across all operative phases with 689 (50%, Fig. [2](#Fig2){ref-type="fig"}) taking place during pelvic tasks; however, no difference between the trial arms was seen (total 322 vs. 367, median 8 per case (6--12) vs. 8 (6--11), *p* = 0.854) or by pelvic location (Supplementary Table 1 + Supplementary Fig. 1).

Fig. 2**A--C** Intraoperative error data. **A** Box and whisker plot, **B** histogram, **C** errors per operative phase. No differences in the distributions are seen. Errors were seen to take place across all phases of the operation justifying the approach to review entire cases. Studying pelvic performance alone would have missed 50% of identified adverse events

Table 4OCHRA categorical data2D3DSumSum*p*Number of laparoscopic TME cases3740Errors---dissection/instrument use Poor visualisation of tip45460.415 Overshoot of movement64480.05 Instrument applied with too little distance to structure59530.428 Inappropriate use of diathermy/energy source15160.995 Incorrect amount of energy applied36550.426 Dissection performed in wrong direction40280.086 Diathermy/dissection in wrong tissue plane1361450.801 Use of inappropriate energy to dissect27190.415 Cutting without lifting tissues from underlying structures18130.404Errors---retraction/tissue handling errors Avulsion of tissue27330.837 Too much blunt force applied to tissue73880.340 Traction applied with too much tension47650.306 Traction applied with too little tension23170.426 Traction applied in wrong direction16140.911 Inappropriate handling of tumour330.921 Inappropriate grasping/blunt handling of structure42510.541 Use of inappropriate instrument to retract7130.288Consequences Bleeding (ooze)2292330.558 Bleeding (significant/pulsatile)25440.365 Mesorectal injury---breech of fascia only37470.324 Mesorectal injury---into mesorectal fat29510.154 Mesorectal injury---exposing rectal adventitia1060.402 Mesorectal injury---into rectal musculature110.956 Rectal perforation510.074 Diathermy burn to viscus31330.553 Sharp injury to viscus460.38 Blunt bowel injury15150.821 Perforating bowel injury120.605 Diathermy burn to other structure11110.599 Sharp injury to other structure220.937 Risk of pelvic nerve injury19170.713 Injury to pelvic nerves20150.54 Injury to pelvic fascia19120.253 Injury to ureter001 Risk of injury to other structure19260.561 Injury to other structure19220.957 Delay to progress of operation10130.36 Oncological compromise of operation370.337External error mode Step not done24230.394 Step partially completed30360.838 Step repeated21190.48 Second additional step14100.892 Second step performed instead030.171 Step out of sequence350.531 Step done with too much force, speed, depth, distance, time or rotation2372630.841 Step done with too little force, speed, depth, distance, time or rotation58610.454 Step done in wrong orientation, direction or point in space1671700.603 Step done on/with wrong object1121110.472Instrument Hook diathermy1381230.528 Finger switch diathermy100.298 Ultrasonic dissection2492870.846 Johann grasper2082070.347 Fine grasper360.608 Swab430.895 Suction6110.853 Scissors4130.136 Stapler24150.104 Bowel clamp020.336 Clip applicator6100.191 Retractor110.956 Other instruments21200.348Hierarchical surgical task phase Setup42680.317 Vascular pedicle1211030.174 Colonic mobilisation90870.406 Splenic flexure85700.329 Posterior TME1221520.374 Anterior TME60700.766 Distal TME941100.922 Resection and anastomosis47350.142 Completion, stoma and closure8120.507All figures represent the sum of observed events. The number and nature of observed adverse events are in keeping with those expected for expert performed laparoscopic total mesorectal surgery with serious events infrequently seen. The only identified difference is a reduction of overshoot errors in the 3D cases as could result from an increase in depth perception provided by stereopsis

Surgeon cognitive load {#Sec16}
----------------------

Surgeons reported low demands across all six domains of the NASA-TLX with no statistical or clinically relevant differences seen between the trial arms (Fig. [3](#Fig3){ref-type="fig"}).

Fig. 3NASA-TLX with medians displayed (2D---dashed line, 3D---solid line). Overall low demands were reported in both arms and were not influenced by the use 2D or 3D imaging (*p* = 0.59, 0.825, 0.64, 0.942, 0.270 and 0.286, respectively)

Specimen analysis {#Sec17}
-----------------

Pathologically assessed tumour stages, relationship to the peritoneal reflection, lymph node yield and circumferential resection margins were equal between 2D and 3D surgery (Table [5](#Tab5){ref-type="table"}). A single R1 resection was observed in each arm (*p* = 0.987). Intention-to-treat analysis showed no difference in mesorectal fascial plane surgery (76% vs. 81%, OR 0.73 (95% CI 0.26--2.08), *p* = 0.163). However, the plane was not reported in eight cases (9.4%) predominantly from 3D patients. When these were excluded, 3D laparoscopy produced clinically but not statistically significant higher rates of mesorectal plane excisions (77% vs. 94%, OR 0.23 (95% CI 0.05--1.16), *p* = 0.059, Fig. [4](#Fig4){ref-type="fig"}).

Table 5Histopathology data2D3D*p*CountColumn *N* (%)CountColumn *N* (%)Tumour stage PCR00.02 (22% PCR rate)4.70.658 11535.71330.2 21331.01534.9 31331.01227.9 412.312.3pT PCR00.024.70.497 149.5614.0 21842.9920.9 31842.92251.2 424.849.3pN 02866.73172.10.687 1921.4614.0 2511.9614.0pM 04197.64297.71 112.412.3Relationship to peritoneal reflection Above2252.41841.90.188 Astride819.0614.0 Below1228.61944.2Circumfrential resection margin (mm, median, IQR)17.0 (10--25)11.0 (6--18)0.088Lymph node yield total (median, IQR)19 (15--27)19 (14--26)0.912Plane of mesorectal excision Mesorectal3276.23581.40.163 Intramesorectal49.512.3 Muscularis propria49.512.3 Not reported24.8614R status 04197.64297.70.987 11 (CRM 0.8 mm)2.41 (distal margin \< 1 mm)2.3No differences are observed between the arms although a clinically relevant but non-significant increase in mesorectal plane surgery is seen in the 3D arm. PCR---Pathological complete response to neoadjuvant chemotherapy

Fig. 4Histopathological assessment of the mesorectal surgical plane. Despite inclusion in the UK Royal College of Pathologists colorectal cancer dataset was not given in eight (9.4%) reports. When these are excluded a clinically significant increase in mesorectal fascial plane surgery is seen (87% overall, 77% vs. 94%, OR 0.23 (95% CI 0.05--1.16), *p* = 0.059)

Discussion {#Sec18}
==========

With the present debate on the role of MAS in rectal cancer surgery, appraisal of novel technology that may positively impact on outcomes is required. There has been an uptake in 3D laparoscopy in clinical settings despite little evidence to support its use. Since there was no prior research, and as advocated by the IDEAL collaboration on surgical innovation, it was important to perform a developmental study in order to assist the design a future definitive RCT \[[@CR18]\]. Feasibility of the methodology and multicentre recruitment was also needed given the time and resource implications of major trials. Here, we incorporated all methodological recommendations for multicentre laparoscopic colorectal RCTs and 3D studies \[[@CR14], [@CR17], [@CR19]\] and report the first TME trial using 3D laparoscopy.

Assisted by video capture technology integrated in most MAS platforms, we deliberately studied the frequently overlooked intraoperative period as it was felt this is where any impact of imaging technology was most likely to be seen. It was hoped this could provide new insights into trial findings and identify areas for targeted improvements. Using the validated, structured OCHRA technique which we previously successfully applied to the assessment of intraoperative specialist performance and as the primary endpoint of a multicentre TME RCT, provision of stereoscopic imaging did not alter the number of enacted error events. Although a margin of 30% was selected, the observed difference was nominal supporting our approach to perform this preliminary trial. Video review is hindered by its time-intensive nature and importantly did not link operative performance to specimen results. Therefore, its relevance is questionable and appears redundant in future TME studies.

Optimal oncological outcomes are obtained through achieving a complete TME resection including clear circumferential margins and mesorectal fascial plane surgery \[[@CR1], [@CR2], [@CR4], [@CR5], [@CR31]--[@CR33]\]. Our main finding was the potential improvement in TME specimen quality following 3D laparoscopy. No other differences were observed across any other outcome. 94% of 3D TME specimens were assessed as mesorectal fascial plane representing a clinically, but borderline statistically, significant improvement over 2D surgery. This figure exceeds the results reported by major laparoscopic rectal cancer trials including their open and robotic arms \[[@CR6], [@CR9], [@CR10], [@CR34]\]. Resection in the mesorectal fascial plane is associated with reduced local and distant recurrence and improvements in disease-free and overall survival. This result and the very low CRM involvement rate can be expected to lead to low rates of recurrence and together with the acceptable conversion, leak and re-operation rate support the ongoing use of laparoscopy by specialist surgeons. It should be noted that reflecting our exclusion of abdominal-perineal resections the average tumour height was slightly higher than the major trials and lower neoadjuvant use was seen in keeping with UK guidelines and practice.

Across all other pre-defined endpoints, equivalence between the 2D and 3D trials arms was seen. The equal operative, cognitive load and patient outcome data suggest specialist performance was not altered by the imaging technology used. It is possible their experience has overcome the lack of depth perception inherit to 2D laparoscopy. No meaningful surgeon side effects were encountered and no deterioration in cognitive load was seen suggesting contemporary 3D platforms have indeed overcome past deficiencies \[[@CR13], [@CR16]\]. Our results are strengthened by the use of centralised randomisation with allocation concealment, standardised equipment across all centres, stereopsis testing, blinded video assessment and independent histopathology and morbidity data collection.

Given the current literature concerns regarding laparoscopic TME specimen quality, our findings warrant further exploration. Mesorectal plane of excision should be adopted as the primary endpoint for a future larger multicentre RCT and would be additionally strengthened by the use of centralised, protocol-led specimen review. Our study design was agreeable to patients, surgeons and theatre teams resulting in acceptable recruitment with low attrition which should be reproducible across additional sites. Should a definitive study confirm our findings this would represent an easily implemented and generalisable route to quality improvement whilst delivering the short-term recovery benefits presented by MAS \[[@CR7], [@CR12]\]. Outside this endpoint, the equivalence of all other data does not support undertaking larger trials. To provide homogeneity, we excluded abdominal-perineal and trans-anal TME excisions. Although the need for a complete specimen is unaltered, variation in perineal and low rectal technique could have directly influenced histopathology results. The health economics of 3D laparoscopy have not been sufficiently reported to date although a recent health technology assessment suggested the additional cost per patient for 3D systems in general surgery could be as low as €1.67 \[[@CR15]\]. Our data suggest no meaningful secondary impact on healthcare resources could be expected.

Surgical intervention research presents specific challenges but the need for evidence-based practice remains including in the use of theatre technologies \[[@CR18]\]. It remains surprising that surgical technology undergoes intensive development and testing to obtain licencing but clinical research assessment is not mandatory. This is in direct contradiction to the extensive regulatory requirements for other healthcare interventions such as pharmaceuticals. The few randomised clinical 3D studies have also shown equivalent results going back over 20 years \[[@CR35]\]. Randomisation removes many of the inherent biases that can unduly influence comparable studies. Our trial surgeons subjectively praised 3D systems and were surprised when data were unblinded in a similar fashion to other colorectal MAS technology trials \[[@CR34], [@CR36]\]. The majority of 3D laparoscopy studies have used box trainers and laparoscopically naïve participants limiting the applicability to OR performance \[[@CR16], [@CR17]\].

This study should be considered in view of its limitations. In nearly 10% of cases, no mesorectal plane assessment was given despite being a core requirement for TME histology reporting. These data may have influenced our conclusions, but early identification of this issue shows the strength of undertaking preliminary studies and will improve future RCT design. Although we successfully met our aims, as a developmental study with a modest sample size, firm conclusions should not be drawn. We complied with the CONSORT criteria however laparoscopic case selection bias cannot be fully excluded as pre-operative decision making and open TME surgery performed at each centre during the study timeframe were not captured. Although cognitive load was measured, case video does not capture human factors including team experience, interaction and distraction that could influence surgeon performance or the extracorporeal operative tasks. The 500 h of video analysis undertaken here highlights the limited applicability to routine clinical practice. Finally, the results obtained reflect the expertise of the participating surgeons and their centres and cannot be assumed to be applicable to trainees or inexperienced laparoscopic TME surgeons.

Conclusion {#Sec19}
==========

Feasibility of performing multicentre 3D laparoscopic multicentre trials of specialist performed complex procedures is shown. 3D imaging did not alter the number of intraoperative adverse events; however, a potential improvement in mesorectal specimen quality was observed and should form the focus of future 3D laparoscopic TME trials.
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